Venetoclax (ABT199) CAS#:
1257044-40-8
Why my color is so yellow?
Because HPLC more than 99%, Impurity is too less.
So my color is so
beautiful.
Venetoclax (ABT199) CAS#:
1257044-40-8, 12 Intermediates, 15 Impurity.
All from GMP, ISO
plant.
Batch size is more than
50kg.
Yellow is
Quality.
Description: Venetoclax, also known as ABT-199 or GDC0199, is an orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. Venetoclax mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells.
Name: Venetoclax (ABT199)
CAS#: 1257044-40-8
Chemical Formula: C45H50ClN7O7S
Exact Mass: 867.3181
Molecular Weight: 868.44
Elemental Analysis: C, 62.24; H, 5.80; Cl, 4.08; N, 11.29; O, 12.90; S, 3.69
2017 China CPHI: E1M35
EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
労働時間: Beijing Time 4:00AM~11:00PM
郵箱: info@eosmedchem.com ; eosmedchem@gmail.com
辦公室: 0086-531-69905422-806(直通)
攜帶番號 & WhatsApp & Wechat: +8618653174435
住所: Diaozhen Chemical Industrial Park, Jinan City, China
Skype: willgutian
QQ: 2393923585
REFERENCES
1: Seymour J. ABT-199 for Chronic Lymphocytic Leukemia. Clin Adv Hematol Oncol. 2014 Oct;12(10):698-700. PubMed PMID: 25658896.
2: Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, Hsi ED, Almasan A. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015 Jan 15;6:e1593. doi: 10.1038/cddis.2014.525. PubMed PMID: 25590803.
3: Cao Y, Yang G, Hunter ZR, Liu X, Xu L, Chen J, Tsakmaklis N, Hatjiharissi E, Kanan S, Davids MS, Castillo JJ, Treon SP. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4(Wild-type) and CXCR4(WHIM) mutated Waldenstrom macroglobulinaemia cells. Br J Haematol. 2015 Jan 12. doi: 10.1111/bjh.13278. [Epub ahead of print] PubMed PMID: 25582069.
4: Johnson-Farley N, Veliz J, Bhagavathi S, Bertino JR. ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells. Leuk Lymphoma. 2015 Jan 28:1-7. [Epub ahead of print] PubMed PMID: 25373508.
5: Ko TK, Chuah CT, Huang JW, Ng KP, Ong ST. The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors. Oncotarget. 2014 Oct 15;5(19):9033-8. PubMed PMID: 25333252; PubMed Central PMCID: PMC4253416.
6: Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K, de Bock CE, Degryse S, Canté-Barrett K, Briot D, Clappier E, Lammens T, De Moerloose B, Benoit Y, Poppe B, Meijerink JP, Cools J, Soulier J, Rabbitts TH, Taghon T, Speleman F, Van Vlierberghe P. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014 Dec 11;124(25):3738-47. doi: 10.1182/blood-2014-05-574566. Epub 2014 Oct 9. PubMed PMID: 25301704.
7: Zhao X, Bodo J, Sun D, Durkin L, Lin J, Smith MR, Hsi ED. Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. Br J Haematol. 2015 Mar;168(5):765-8. doi: 10.1111/bjh.13149. Epub 2014 Oct 4. PubMed PMID: 25284608.
8: ABT-199 shows effectiveness in CLL. Cancer Discov. 2014 Sep;4(9):OF7. doi: 10.1158/2159-8290.CD-NB2014-102. Epub 2014 Jul 3. PubMed PMID: 25185206.
